Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors

Clin Infect Dis. 1998 Jul;27(1):100-6. doi: 10.1086/514610.

Abstract

A retrospective case-control study was conducted to determine why some infants born full-term without obstetric intervention to hepatitis B e antigen (HBeAg)-seropositive mothers become infected by hepatitis B virus (HBV) despite having received passive-active immunoprophylaxis. Cases and controls comprised 12 hepatitis B surface antigen (HBsAg)-seropositive infants and 22 HBsAg-seronegative infants, respectively. Infants infected by putative vaccine-escape mutants were excluded. Risk factors, after adjustment for the level of maternal viremia, were the following allelic base changes in maternal HBV:C158, A328, G365, and A479 (P = .017, .005, .003, and .005, respectively). High-level maternal viremia (i.e., > or = 10(8) genome equivalents/mL) was a significant factor only after adjustment for G365 (P = .027). HBV DNA sequences recovered from one of the cases, the case's mother, and three infected contacts all had the high-risk mutations. Specific allelic mutations in maternal HBV and level of maternal viremia are potential predictors of vertical breakthrough infection.

MeSH terms

  • Case-Control Studies
  • DNA, Viral / analysis*
  • Female
  • Hepatitis B / congenital
  • Hepatitis B / immunology
  • Hepatitis B / prevention & control*
  • Hepatitis B / transmission*
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Vaccines / administration & dosage*
  • Hepatitis B e Antigens / blood
  • Hepatitis B virus / genetics*
  • Hepatitis B virus / immunology
  • Humans
  • Immunization, Passive
  • Immunoglobulins / administration & dosage*
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Mutation
  • Pregnancy
  • Pregnancy Complications, Infectious / immunology*
  • Pregnancy Complications, Infectious / prevention & control*
  • Retrospective Studies
  • Risk Factors
  • Treatment Failure
  • Vaccination

Substances

  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Hepatitis B e Antigens
  • Immunoglobulins
  • hepatitis B hyperimmune globulin